Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Lorlatinib · Lorbrena

Small molecule · Inhibitor of anaplastic lymphoma kinase (ALK) and ROS1 proto-oncogene receptor tyrosine kinase (ROS1) · developed by Pfizer

Approved FDA, Nov 2018
PFE Developer

What is Lorlatinib?

Lorlatinib is a kinase inhibitor that acts on ALK and ROS1 and shows in vitro activity against several other kinases, including TRK family members, TYK2 and FAK. It inhibits ALK phosphorylation, including forms carrying resistance mutations, and has antitumor activity in models with EML4-ALK fusions, including intracranial tumors. It is used in ALK-positive metastatic non-small cell lung cancer and is being studied in advanced malignancies, solid tumors, ovarian cancer and urothelial cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Lorbrena, Lorlatanib
Drug type
Small molecule
Targets
anaplastic lymphoma kinase (ALK), ROS1 proto-oncogene receptor tyrosine kinase (ROS1), neurotrophic receptor tyrosine kinases TRKA/TRKB/TRKC (NTRK1) (secondary target), tyrosine kinase TYK2 (TYK2) (secondary target), focal adhesion kinase (PTK2) (secondary target)
Mechanism
Inhibitor of anaplastic lymphoma kinase (ALK) and ROS1 proto-oncogene receptor tyrosine kinase (ROS1)
Therapy area
Oncology
Developer
Pfizer (PFE)
FDA status
Approved as Lorbrena (November 2, 2018), NDA210868 · FDA label
UNII
OSP71S83EU

✅ FDA-approved uses

From the indications section of the FDA label (version of Jun 26, 2026). Read the full label for the exact wording, limitations and safety information.

Conditions studied

Advanced MalignanciesNSCLCOvarian CancerSolid TumorsUrothelial Cancer

Other drugs acting on ALK / ROS1

More from Pfizer

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the PFE page.

Follow PFE, the company behind Lorlatinib

See PFE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

PFE catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.